What is Zacks Research’s Forecast for APLS Q2 Earnings?

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Stock analysts at Zacks Research reduced their Q2 2025 earnings estimates for Apellis Pharmaceuticals in a research note issued on Tuesday, May 27th. Zacks Research analyst R. Department now forecasts that the company will earn ($0.46) per share for the quarter, down from their previous estimate of ($0.34). The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.70) per share. Zacks Research also issued estimates for Apellis Pharmaceuticals’ Q3 2025 earnings at ($0.44) EPS, Q4 2025 earnings at ($0.42) EPS, FY2025 earnings at ($2.06) EPS, Q1 2026 earnings at ($0.48) EPS, Q2 2026 earnings at ($0.41) EPS, Q3 2026 earnings at ($0.38) EPS, Q4 2026 earnings at ($0.40) EPS, FY2026 earnings at ($1.67) EPS, Q1 2027 earnings at ($0.30) EPS and FY2027 earnings at ($0.42) EPS.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.38). Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The business had revenue of $149.90 million during the quarter, compared to analyst estimates of $197.61 million. During the same quarter last year, the company posted ($0.54) earnings per share. The company’s revenue was down 3.2% on a year-over-year basis.

A number of other brokerages also recently issued reports on APLS. Robert W. Baird reduced their price objective on shares of Apellis Pharmaceuticals from $55.00 to $47.00 and set an “outperform” rating on the stock in a research note on Thursday, May 8th. Wells Fargo & Company reduced their price target on shares of Apellis Pharmaceuticals from $30.00 to $26.00 and set an “equal weight” rating on the stock in a research note on Thursday, May 8th. Needham & Company LLC reduced their price target on shares of Apellis Pharmaceuticals from $40.00 to $29.00 and set a “buy” rating on the stock in a research note on Wednesday, May 7th. The Goldman Sachs Group reduced their price target on shares of Apellis Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating on the stock in a research note on Monday, March 3rd. Finally, HC Wainwright restated a “buy” rating and issued a $57.00 price target on shares of Apellis Pharmaceuticals in a research note on Monday, March 3rd. Nine research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $39.89.

Apellis Pharmaceuticals Trading Up 3.6%

Shares of Apellis Pharmaceuticals stock opened at $17.41 on Friday. The company has a market capitalization of $2.19 billion, a price-to-earnings ratio of -8.58 and a beta of 0.73. The company has a quick ratio of 3.73, a current ratio of 4.36 and a debt-to-equity ratio of 1.91. Apellis Pharmaceuticals has a 12-month low of $16.10 and a 12-month high of $43.76. The firm’s 50-day moving average price is $19.05 and its two-hundred day moving average price is $26.02.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in APLS. EverSource Wealth Advisors LLC increased its stake in shares of Apellis Pharmaceuticals by 2,707.1% in the 4th quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company’s stock valued at $25,000 after acquiring an additional 758 shares in the last quarter. Assetmark Inc. increased its stake in shares of Apellis Pharmaceuticals by 3,938.7% in the 1st quarter. Assetmark Inc. now owns 1,252 shares of the company’s stock valued at $27,000 after acquiring an additional 1,221 shares in the last quarter. Signaturefd LLC increased its stake in shares of Apellis Pharmaceuticals by 357.2% in the 4th quarter. Signaturefd LLC now owns 1,175 shares of the company’s stock valued at $37,000 after acquiring an additional 918 shares in the last quarter. GF Fund Management CO. LTD. increased its stake in shares of Apellis Pharmaceuticals by 21.9% in the 1st quarter. GF Fund Management CO. LTD. now owns 3,185 shares of the company’s stock valued at $70,000 after acquiring an additional 573 shares in the last quarter. Finally, US Bancorp DE increased its stake in shares of Apellis Pharmaceuticals by 70.0% in the 4th quarter. US Bancorp DE now owns 3,223 shares of the company’s stock valued at $103,000 after acquiring an additional 1,327 shares in the last quarter. Institutional investors own 96.29% of the company’s stock.

Insiders Place Their Bets

In other Apellis Pharmaceuticals news, General Counsel David O. Watson sold 5,569 shares of the firm’s stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $25.10, for a total transaction of $139,781.90. Following the completion of the transaction, the general counsel now owns 138,730 shares in the company, valued at approximately $3,482,123. This trade represents a 3.86% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 6.50% of the company’s stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).